STAT5B is a dual-function signal transducer and transcription activator 1 critical for growth and immune regulation. Mechanistically, STAT5B mediates the growth hormone receptor-JAK2-STAT5B signaling cascade to regulate insulin-like growth factor (IGF)-I production, the primary driver of postnatal growth 23. STAT5B also activates GATA1 expression in hematopoietic cells through direct binding to consensus sequences in gene promoters 4 and regulates mammary gland development during pregnancy via lactogenic hormone signaling 5. Notably, STAT5A cannot compensate for STAT5B loss despite >95% amino acid identity 2. Clinically, inactivating STAT5B mutations cause Growth Hormone Insensitivity Syndrome with severe postnatal growth failure and marked IGF-I deficiency 23. Uniquely, autosomal recessive STAT5B deficiency presents with primary immunodeficiency including chr17 pulmonary disease, distinguishing it from GH receptor deficiency 26. The SH2 domain is vital for STAT5B activation; specific tyrosine 665 mutations produce opposite effects—Y665F demonstrates gain-of-function with enhanced phosphorylation and transcriptional activity, while Y665H exhibits loss-of-function resembling null activity 75. These mutations distinctly alter immune cell populations and mammary development, illustrating how single nucleotide changes fundamentally alter STAT5B pathophysiology and disease manifestation.